Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision antiplatelet therapy guided by platelet aggregation function in non-cardiogenic ischemic stroke
ChiCTR2200066530Phase 4Recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin in ischemic stroke (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Incidence of platelet hyperreactivity (HOPR) at 30 ± 5 days after enrollment. Started Jan 2023; status: recruiting.
02
Drugs
aspirin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2200066530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066530.